metaEvidence - overview

button bars forest bayes pooled summary circles


			Statistically conclusive or suggested result	Inconclusive results	Uncertain results	Safety results
es-BC - TNBC - NA - all population breast cancer - triple negative es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA) es-BC - TNBC - NA - all population
versus placebo
	olaparib vs. placebo	1	none	-	statistically conclusive 32 % decrease in deaths (OS) but the degree if certainty is unassessable statistically conclusive 42 % decrease in iDFS but the degree if certainty is unassessable	-
es-BC - TNBC - NA - PDL1 positive breast cancer - triple negative es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA) es-BC - TNBC - NA - PDL1 positive
mBC - Triple negative (TNBC) - 1st Line (L1) breast cancer - triple negative mBC - Triple negative (TNBC) - 1st Line (L1)
mBC - TNBC - L1 - all population breast cancer - triple negative mBC - Triple negative (TNBC) - 1st Line (L1) mBC - TNBC - L1 - all population
versus Standard of Care (SoC)
	veliparib plus paclitaxel plus carboplatin vs. Standard of Care (SoC)	2	statistically conclusive 45 % increase in pCR	inconclusive results for: deaths (OS); events or deaths (EFS); AE leading to treatment discontinuation (any grade)	-	-
mBC - TNBC - L1 - PDL1 positive breast cancer - triple negative mBC - Triple negative (TNBC) - 1st Line (L1) mBC - TNBC - L1 - PDL1 positive
mBC-Triple negative (TNBC) - 2nd Line (L2) breast cancer - triple negative mBC-Triple negative (TNBC) - 2nd Line (L2)
versus Standard of Care (SoC)
	talazoparib vs. Standard of Care (SoC)	1	none	inconclusive results for: deaths (OS); DOR	statistically conclusive 46 % decrease in progression or deaths (PFS) but the degree if certainty is unassessable statistically conclusive 5.0-fold increase in objective responses (ORR) but the degree if certainty is unassessable	-
mBC - TNBC - L2 - all population breast cancer - triple negative mBC-Triple negative (TNBC) - 2nd Line (L2) mBC - TNBC - L2 - all population
versus Standard of Care (SoC)
	olaparib vs. Standard of Care (SoC)	1	none	inconclusive results for: deaths (OS); DOR	statistically conclusive 42 % decrease in progression or deaths (PFS) but the degree if certainty is unassessable suggested 3.7-fold increase in objective responses (ORR) but the degree if certainty is unassessable	-
mBC - TNBC - L2 - PDL1 positive breast cancer - triple negative mBC-Triple negative (TNBC) - 2nd Line (L2) mBC - TNBC - L2 - PDL1 positive